References

Charité IDE randomized trial, 304 patients, 2 years: clinical outcomes at least equivalent to ALIF; satisfaction 73.7% vs 53.1%; reoperation 5.4% vs 9.1%.

Charité IDE trial at 5 years: outcomes equivalent to fusion; index-level motion 6.0 degrees vs 1.0 after fusion; reoperation 7.7% vs 16.3%; 78% vs 72% satisfied.

ProDisc-L IDE randomized trial, 286 patients, 2 years: noninferior to circumferential fusion; 93.7% of patients had a normal range of motion (mean 7.7 degrees).

ProDisc-L IDE trial at 5 years: noninferior to fusion; 77% satisfied in both arms; 82.5% vs 68% would have the surgery again; index reoperation 8% vs 12%; motion maintained with no spontaneous fusion.

activL IDE randomized trial, 324 patients, 2 years: noninferior to ProDisc-L and Charité controls; reoperation 2.3%.

Norwegian randomized trial of disc replacement vs multidisciplinary rehabilitation at 8 years: ODI difference 6.1 points favouring surgery (below the minimal clinically important difference); 24% of rehabilitation patients crossed over to surgery; 14% of surgical patients had further surgery.

Same Norwegian trial at 8 years: adjacent disc degeneration progressed in 42% after disc replacement and 40% after nonoperative treatment.

Charité, 100 patients, minimum 10 years: 90% excellent or good; 91.5% returned to work; mean motion 10.3 degrees; posterior fusion required in 5%.

Charité, 106 patients, mean 13.2 years (minimum 10): 82.1% excellent or good; 90.6% of implants still mobile, mean 10.1 degrees; fusion for failure 7.5%; adjacent segment disease 2.8%.

ProDisc-II, 54 patients, 10 years: in well-selected patients success 76.9% and satisfaction 87.2%, in poorly selected 40% and 60%; revision fusion 9.3%.

Danish cohort, 57 of 68 patients, mean 10.6 years: back pain VAS 6.8 to 3.2; 33% underwent revision to fusion; 52.6% would choose the operation again.

Charité III, 30 patients, mean 15.2 years, the longest published follow-up: 93.3% clinical success, 100% implant survival; index-level motion decreased over time with heterotopic ossification in most segments.

Single center, 2,141 lumbar disc replacement patients over 20 years (mean follow-up 6.6 years; 258 patients beyond 15 years): device removal or revision in 1.26%.

ProDisc-L IDE trial at 5 years: radiographic adjacent-level degeneration 9.2% after disc replacement vs 28.6% after fusion; adjacent-level surgery 1.9% vs 4.0% (not significant).

1,000 lumbar disc replacements: reoperation at an adjacent segment 2.0%, compared with about 4.5% reported after fusion.

Systematic review of 27 studies: adjacent segment disease 14% after fusion vs 1% after arthroplasty; adjacent segment degeneration 34% vs 9% (class C evidence).

Meta-analysis of four randomized trials at 5 years: disc replacement vs fusion, reoperation relative risk 0.52; satisfaction relative risk 1.13.

Meta-analysis of 13 randomized trials, 2,349 patients: reoperation 6.1% after disc replacement vs 11.9% after fusion; adjacent segment disease 3.7% vs 8.3%; patient-reported outcomes converge by 5 years.

Systematic review of 22 studies with at least 5 years of follow-up (2,284 patients, mean 8.3 years): clinical success 74.8%; satisfaction 86.3%; reoperation 13.6%; complications 18.5%.

Retrieval analysis of 21 Charité cores implanted 1.8 to 16 years: mean polyethylene wear about 0.3 mm; rim cracks in 52%; one case of osteolysis.

Periprosthetic tissue after revision of lumbar disc replacements shows polyethylene particles and inflammatory reactions comparable to those around hip and knee replacements.

Retrograde ejaculation after anterior lumbar surgery in men: 9.8% after disc replacement vs 7.4% after anterior fusion with BMP.

Vascular complications in lumbar disc replacement: 2.0% overall, with age as a risk factor.

Systematic review and meta-analysis of registries: about 82% of total knee replacements last 25 years.

Modern total knee arthroplasty failures: loosening 39.9% and infection 27.4% are the leading causes; polyethylene wear is no longer a major cause.

Medicare National Coverage Determination 150.10 (effective August 14, 2007): lumbar artificial disc replacement is not covered for beneficiaries over 60; for those 60 and under there is no national determination and coverage is at the regional contractor's discretion.

Swedish randomized trial, 152 patients, 5 years, 99.3% follow-up: totally pain-free 38% after disc replacement vs 15% after fusion; ODI 17 vs 23; back pain VAS 23 vs 31; no difference in complications or reoperations.

Same Swedish trial at 2 years: pain-free 30% vs 15%; disc replacement patients reached maximum recovery by 1 year while fusion patients took 2 years.

39 athletes after lumbar disc replacement: 94.9% returned to sport, 38.5% within 3 months and a further 30.7% by 6 months; performance improved in 84.6%.

activL IDE trial, 7-year results, 283 patients: opioid use 0% at 7 years in both arms; overall reoperation 4.6%; activL noninferior to ProDisc-L with better flexion-extension motion.

US National Inpatient Sample 2010 to 2019, 8,049 lumbar disc replacements vs 1.13 million fusions, matched: any complication 7.0% vs 13.2%; transfusion 3.1% vs 8.1%; length of stay 0.65 day shorter; cost $4,529 lower.

Claims-database comparison of single-level arthroplasty and anterior interbody fusion: stay 2.17 vs 1.04 days (longer for arthroplasty) but readmission 0.71% vs 2.6%; a balancing source on hospital stay.

130 patients, mean 13.9 years after lumbar disc prosthesis: 73.8% still in their original job, 13.8% in an alternative role; reoperation 12.3%; no prosthesis revision.

Charité in workers' compensation patients, 17-year follow-up: 81% returned to work and worked a mean of 9.1 years after surgery; 94% satisfied; 38% had further surgery (16 patients reached).

Economic analysis of the Swedish randomized trial: health-care cost significantly lower for disc replacement (by about SEK 23,000); societal cost and quality-adjusted life years similar; sick leave 185 vs 252 days (not significant).

Five-year randomized comparison of two lumbar discs (Kineflex vs Charité): similar outcomes and about 11% reoperation in each arm.

Database study: facet joint injections after lumbar disc replacement 11.5% vs 6.4% after fusion at 5 years, with no difference in reoperation; a balancing source on facet pain.

Matched database comparison (1,625 vs 1,625): adjacent segment disease similar (RR 0.93); 30-day revision lower after arthroplasty (RR 0.24); lower cost and length of stay.

Approved 2006 (single level) and April 2020 (one or two contiguous levels L3-S1): skeletally mature patients with degenerative disc disease confirmed by history and imaging, no more than grade 1 spondylolisthesis, after at least 6 months of failed conservative care. Contraindications include DEXA T-score below -1.0, bony stenosis, pars defect or lytic spondylolisthesis, isolated radicular syndrome, infection, metal allergy and small endplates.

Approved June 2015 for one level at L4-5 or L5-S1 in skeletally mature patients with degenerative disc disease after at least 6 months of conservative care and no more than grade 1 spondylolisthesis. Contraindications include T-score of -1.0 or worse, facet degeneration or ankylosis, stenosis, spondylolysis, scoliosis, disc height under 3 mm, multilevel symptoms, infection and allergy.

Last review September 18, 2026. Lumbar disc arthroplasty criteria: age 18 to 60; single level L3-S1; pain over 5/10; at least 6 months of supervised multimodal care including at least 3 months of in-person physical therapy in the past year; radiographs and MRI or CT within 6 months; T-score not below -1.0; exclusions include listhesis over 3 mm, stenosis, pars defect, scoliosis over 11 degrees, facet ankylosis or severe degeneration, disc height under 2 mm, prior fusion combination; HbA1c under 8% if diabetic; unmanaged mental-health disorder excluded; multilevel experimental.

Effective August 4, 2026: age 18 to 60; single level L3-S1; at least 6 consecutive months of structured care failing both prescription medication and provider-directed exercise; no facet ankylosis or severe facet degeneration; T-score below -1.0 excluded; listhesis over 3 mm, stenosis, pars defect, scoliosis over 11 degrees, disc height under 3 mm excluded; no unmanaged behavioral-health disorder.

Effective September 19, 2026: age 18 to 60; at least 6 months of multifaceted care (physical therapy plus one complementary treatment); single level, or two levels only with a two-level FDA device at L3-S1; MRI showing moderate to severe degeneration with Modic changes; pain 4/10 or more or functional limitation; T-score of -1.0 or worse, facet arthropathy, pars defect, prior fusion at the level and stenosis excluded; tobacco abstinence and weight loss at BMI 40 or more strongly recommended.

Effective February 1, 2026: single-level lumbar disc arthroplasty with an FDA-approved device in skeletally mature patients with intractable discogenic back pain, applying proprietary InterQual criteria; hybrid constructs, arthroplasty adjacent to a prior fusion and multilevel arthroplasty are unproven.

Last review May 2020: skeletally mature; single FDA-labeled level; at least 6 months of nonoperative care; osteoporosis or osteopenia, stenosis, pars defect and radicular syndrome excluded; multilevel, off-label level and arthroplasty after prior fusion investigational. Requests are reviewed through TurningPoint under Horizon's surgical management program.